MedTrace Logo

Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)

NCT02278445 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-12-02

No results posted yet for this study

Summary

Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS (Lung Doppler Signals) signals that are related to pulmonary hypertension. The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Conditions

Interventions

RADIATION

Doppler ultrasound

Recording Doppler ultrasound noninvasively from the right chest wall

DEVICE

Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)

Sponsors & Collaborators

  • Echosense Ltd.

    lead INDUSTRY

Principal Investigators

  • Merav Lidar, Dr · Sheba medical center, Rheumatology department

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278445 on ClinicalTrials.gov